AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...

After years of disappointment, things might seem to be looking up for the amyotrophic lateral sclerosis patient community. Two weeks ago they got a new drug approved by the FDA, and now French biotech ...

AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Paris, October 10, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...

Analysts have torn into AB Science over the clinical trial compliance failings identified by regulators in France. Oddo took the most extreme action by slashing its price target from €48 ($53) to €5, ...

Update on the AB8939 microtubule program and in particular on the ability of AB8939 to generate a response on MECOM rearrangement AB Science provided an update on the microtubule program AB8939.

The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. The issue of the ABSAs, ...

AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AB Science SA (Euronext - FR0010557264 - AB) ...

AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating ...

AB SCIENCE WILL PARTICIPATE IN THE BIOMED FORUM INVESTORS CONFERENCE Paris, 22 january 2024, 7pm CET AB Science SA (Euronext – FR0010557264 – AB) announced that its management team will participate in ...